Kornimate/medical-research-clean huggingface dataset:
activated protein c in severe acute pancreatitis

Conditions: Acute Pancreatitis

Summary: activated protein c (apc)has been shown to reduce mortality in severe sepsis(bernard et al. 2001b). the clinical picture of severe acute pancreatitis (ap) is similar to that of sepsis. the investigators conducted a randomised double-blinded placebo-controlled pilot study in ap patients (16+16) with the same dose of apc that has been proven to be efficacious and safe in septic patients. the aim of the study is to investigate whether the apc replacement therapy diminishes the occurrence and severity of organ dysfunction in patients with severe ap. the effect of apc on inflammatory and hemostatic parameters is also assessed.

the study started in 2003 and was finished in 2007. the study was registered in the helsinki university central hospital study register in 2003.

Eligibility criteria:
inclusion criteria: * admitted to hospital within 72 h of the onset of pain. * plasma amylase concentration more than three times the upper limit of the normal range and/or ct findings compatible with ap. * organ failure and \<48h of the onset of the first organ failure exclusion criteria: * hiv / b- or c hepatitis infection * pregnancy or breast feeding * active bleeding * increased risk of bleeding (thrombocytes \ 3.0 * gastrointestinal bleeding within 6 weeks or intracranial stroke within 3 months before the study * intravenous contrast extravasation or other signs (fresh hematoma) suggesting active hemorrhage within the pancreas or in the peripancreatic area on admission ct scan * use of antithrombin iii within 12 h * use of acetylsalicylic acid or glycoprotein iib/ia antagonist within 7 days / thrombolytic therapy within 3 days * surgery requiring general or spinal anaesthesia within 12 h * previous pancreatic surgery * application of an epidural catheter within 48 h

Keywords: acute pancreatitis treatment organ failure activated protein c
different modes of assessment on acupuncture effect on patients with chronic prostatitis/chronic pelvic pain syndrome

Conditions: Chronic Prostatitis; Chronic Pelvic Pain Syndrome

Summary: background: chronic prostatitis/chronic pelvic pain syndrome (cp/cpps) is a common disorder. some studies have indicated that acupuncture may ameliorate the symptoms of cp/cpps. however, results are varied and range widely, perhaps due to different modes of assessment including timepoints, places of assessment, and especially subjective scales. we propose to determine the efficacy of acupuncture relative to sham acupuncture for patients with cp/cpps, and compare different modes of assessment regarding the therapeutic effects of acupuncture. methods: sixty patients with cp/cpps will be randomly assigned to receive either acupuncture or sham-acupuncture (30 patients, each). treatment will be conducted 3 times/week, for 4 weeks. the primary outcomes will each be the change from baseline of the total nih (national institutes of health) cpsi (chronic prostatitis symptom index) score associated with 3 modes of assessment: mode 1, the scale recorded at the hospital within 10minutes after the last session of 4 weeks of acupuncture treatment, in the company of the outcome assessors; mode 2, the scale recorded the same day, but not at the hospital; and mode 3, the scale recorded at the hospital 1 to 3 days after the last acupuncture session. the 3 key secondary outcomes include will be the 3 modes assessment of the changes from baseline of the nih-cpsi total scores in the acupuncture group at week 4 after treatment. analysis was by intention-to-treat, and multiplicity was controlled for with a step-down closed-testing procedure.


Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria according to the nih cp/cpps consensus: discomfort or pain in the pelvic region for at least 3 months in the previous 6 months * 18-50 years * nih-cpsi total score ≥15 exclusion criteria: * urologic disease * residual urine volume ≥100 milliliter (ml) * qmax ≤15ml/s * use 5-alpha reductase inhibitor, alpha-blockers, antibiotics or any other prostatitis-specific medication during previous 1 month * diseases that influence urologic symptoms are multiple sclerosis, multiple system atrophy, stroke, alzheimer disease, parkinson's disease, spinal cord injury, cauda equina injury, and sexually transmitted disease * any acute disease or severe disease requiring treatment
evaluation of lotrafilcon a lenses over a three month period

Conditions: Myopia

Summary: the purpose of this trial is to assess the performance of a lotrafilcon a contact lens over a 3-month period.


Eligibility criteria:
inclusion criteria: * on examination, have ocular findings considered to be "normal" and which would not prevent a subject from safely wearing contact lenses. * be willing and able to follow instructions and meet the schedule of follow-up visits as defined in the informed consent. * be able to wear the study lenses in the available powers. * currently wear contact lenses for a minimum of 5 days a week, and at least 8 hours a day. * other protocol inclusion/exclusion criteria may apply. exclusion criteria: * eye injury or surgery within twelve weeks immediately prior to enrollment for this trial. * pre-existing ocular irritation that would preclude contact lens fitting. * currently enrolled in an ophthalmic clinical trial. * evidence of systemic or ocular abnormality, infection or disease likely to affect successful wear of contact lenses or use of their accessory solutions. * any use of medications for which contact lens wear would be contraindicated, in the opinion of the investigator. * history of corneal refractive surgery. * other protocol inclusion/exclusion criteria may apply.
19gauge fine needle biopsy (fnb) versus 22gauge fnb for endoscopic ultrasound guided liver biopsy (eus-lb)

Conditions: Chronic Liver Disease

Summary: to determine the adequacy of eus-lb using a 19g core needle compared to a 22g core needle in a prospective randomized study.

the 19gauge core and 22gauge core needles have both been used for eus-lb with good success. previous studies have reported good safety and tissue adequacy with both the needles, but the head-on comparison between these two needles is lacking. this is a prospective randomized trial comparing the biopsy specimen adequacy of 19gauge versus 22gauge core needles for eus-lb.

Eligibility criteria:
inclusion criteria: * patients undergoing eus-lb * platelet count \> 50,000 * international normalized ratio (inr) \< 1.5 * age \> 18 years of age * non-pregnant patients exclusion criteria: * age \< 18 years of age * pregnant patients * inability to obtain consent * anticoagulants or anti-platelet agents (excluding aspirin) within the last 7 -10 days * platelet count \< 50,000 * presence of ascites * known liver cirrhosis
nonintervention study on peritoneal metastasis of stage iv gastric cancer

Conditions: Stage IV Gastric Cancer With Metastasis

Summary: this is a non-interventional study，aim to observe the safety and efficiency of different treatment regimen for peritoneal metastasis of stage iv gastric cancer in the real world


Eligibility criteria:
inclusion criteria: * 18 ≤ age * patients with histologically confirmed gastric cancer or gastroesophageal junction adenocarcinoma, stage iv with peritoneal metastasis * didn't received any prior systemic chemotherapy * signed informed consent exclusion criteria: * history of hypersensitivity to fluoropyrimidines, tegafur，gimeracil and oteracil potassium capsules , capecitabine, oxaliplatin or the ingredients of this product * pregnancy or lactation women, * inadequate hematopoietic function： wbc≦3,500/mm3; anc≦1,500/mm3; platelet≦80,000/mm3 * inadequate organ function which is defined as below: total bilirubin \>2 pper limit of normal range (uln); alt / ast \> 2.5 upper limit of normal range (uln); serum creatinine \> 1.5 mg/dl, and ccr \> 60 ml/min (estimated by cockcroft-gault formulation); * symptomatic peripheral neuropathy * receiving a concomitant treatment with other fluoropyrimidines * fluoropyrimidines (dpd) congenital absence * other situations which physicians suggesting are inadaptable for enrollment
tranexamic acid prophylaxis for heterotopic ossification in elbow fracture-dislocation surgery

Conditions: Elbow Dislocation; Heterotopic Ossification

Summary: heterotopic ossification (ho) following elbow fracture-dislocation is a well-recognized condition that can lead to reduced range of motion, increased pain, and the necessity for repeat surgeries. inflammation serves as a pivotal initiating factor in the formation of (ho) following a traumatic event. the inflammatory cascade triggered can lead to the dysregulation of tissue homeostasis, thereby promoting the aberrant formation of ectopic bone. tranexamic acid (txa), a food and drug administration (fda) approved synthetic antifibrinolytic agent, has garnered significant attention for its potential to mitigate the inflammatory response in the context of orthopaedic surgical procedures. this study aims to investigate the hypothesis that reducing soft tissue hematoma during elbow fracture-dislocation surgery through the intraoperative administration of txa, can alleviate the occurrence or severity of ectopic bone formation. methods: a prospective randomized study was conducted on patients with elbow fracture-dislocation who underwent surgery between 2016 and 2022. a total of 50 patients were enrolled and randomly assigned to two groups. the first group received 1 gram of intravenous tranexamic acid before the operation, followed by an additional 1 gram intravenously during wound closure. the second group did not receive any anti-bleeding medication. patients were followed up at intervals of 2 weeks, 6 weeks, 3 months, and as needed after the surgery. at the end of the follow-up period, there were 23 patients in the first group and 24 in the second group, with a median follow-up duration of 12.7 months. all patients did not receive any other form of ho prophylaxis. postoperative radiographs and clinical outcomes were assessed and recorded.


Eligibility criteria:
inclusion criteria: 1. traumatic non-pathological elbow fracture-dislocation. 2. age 18 years or older. 3. presentation within 2 weeks of injury. 4. willingness to participate in the study exclusion criteria: 1. inability to provide consent for research participation. 2. active infection in the operated limb. 3. previous hip fracture. 4. head injury. 5. history of deep vein thrombosis (dvt). 6. history of venous thromboembolism (vte). 7. ischemic heart event within the last six months. 8. stroke (cva) within the last six months. 9. coagulopathies. 10. pregnancy.
vr ultrasound guided breast localization

Conditions: Breast Neoplasm Female

Summary: to determine if a virtual reality simulation will reduce pain and anxiety in patients undergoing an ultrasound guided breast localization procedure (traditional wire, savi scout or a radiofrequency identification tag).

needle localizations for breast cancer surgery are required to identify cancerous tissue before surgery. currently this procedure is done with or without a local anesthetic. patients report anxiety regarding cancer and cancer-related procedures. different types of needle localization may have different pain and anxiety based on their duration, complexity, and invasiveness. this research is designed to determine if vr simulated environment can reduce pain and anxiety. our aim is to study the efficacy of a virtual environment in reducing pain and procedural anxiety. it is intended for patients undergoing an ultrasound guided breast localization procedure that have had an abnormal breast biopsy. the overall aim is to discover an efficacious nonpharmacologic method to lower pain and anxiety during a standard of care procedure.

Eligibility criteria:
inclusion criteria: * informed consent is obtained from the patient * females ≥ 18 years of age * patient is schedule for preoperative ultrasound guided breast localization procedure exclusion criteria: * patient is scheduled for or switched to a stereotactic localization procedure * the patient has motion sickness * the patient has severe cognitive disabilities or language barriers that inhibit study form completion in english * refusal of patient to sign consent

Keywords: virtual reality pain anxiety ultrasound guided needle localization
repeated cannabis administration on experimental pain and abuse liability

Conditions: Cannabis; Pain; Tolerance; Hyperalgesia

Summary: chronic pain is a significant public health concern in the u.s., for which prescription opioids have historically been the standard treatment. this has resulted in striking rates of opioid use disorders and fatal overdoses. identifying non-opioid medications for the management of chronic pain with minimal abuse liability is a public health necessity, and cannabinoids are a promising drug class for this purpose. more than 80% of medicinal cannabis users report pain as their primary medical indication. these patients tend to seek products that are low in delta-9-tetrahydrocannabinol (thc; the primary psychoactive, and thus intoxicating, component of cannabis), and high in cannabidiol (cbd), a cannabinoid that purportedly has therapeutic benefit for pain but does not produce intoxicating effects. however, there are few well-controlled human laboratory studies assessing the efficacy of high-cbd cannabis for pain in the context of abuse, and even less is known regarding the effects of daily repeated use of cannabis on pain and its relationship to abuse liability. the proposed randomized, within-subjects, placebo-controlled 16-day crossover inpatient human laboratory pilot study (n = 16 healthy cannabis users; 8 men, 8 women) will address important gaps in our understanding of the potential therapeutic utility of cannabis for pain: 1) if repeated cannabis use can result in hyperalgesia; 2) if tolerance to the analgesic and abuse-related effects of cannabis develops and is reversible. two distinct modalities of experimental pain will be assessed: the cold pressor test (cpt) and quantitative sensory testing thermal temporal summation (qst-tts), and participants will smoke cannabis 3x/day. throughout the study, experimental pain and abuse-related effects will be assessed, as will sleep and subjective mood assessments. this protocol is currently suspended due to the nyspi human subjects research pause and results cannot currently be analyzed and posted. upon un-suspension, we will analyze the data and post results immediately.


Eligibility criteria:
inclusion criteria: * males/non-pregnant females, 21-60 years old * current cannabis user * able to perform all study procedures exclusion criteria: * use of other illicit drugs * if medical history, physical and psychiatric examination, or laboratory tests performed during the screening process reveal any significant illness that the study physician deems contraindicated for study participation * insensitivity to the cold-water stimulus of the cold pressor test or the heat stimulus of quantitative sensory testing
mannitol - potential role in hemodialysis initiation for reduction of intra-dialytic hypotension

Conditions: Intra-dialytic Hypotension

Summary: kidney failure can result from a variety of conditions and can be temporary or permanent. hemodialysis is available as a replacement treatment to perform the work that the kidneys normally do. however, the dialysis procedure can be associated with rapid changes in the composition of the blood - this may lead to changes in blood pressure and in turn reduced blood supply to important parts of the body. we aim to investigate if giving a medicine (called mannitol) during dialysis may be able to reduce the frequency of these low blood pressure events.


Eligibility criteria:
inclusion criteria: * renal failure requiring intermittent hemodialysis initiation; adult patients aged over 18 years; written informed consent exclusion criteria: * hyponatremia \<130 mmol/l; acute myocardial infarction or stroke in previous 7 days; cardiac transplant; ventricular arrhythmia; unstable angina; use of pressors/midodrine; enrollment in conflicting research study; institutionalized individuals; pregnancy; prisoners; documented allergy to mannitol
use of sodium bicarbonate in patients treated with topiramate

Conditions: Epilepsy; Metabolic Acidosis; Tubular Acidosis; Renal

Summary: effect of oral sodium bicarbonate therapy on renal tubular acidosis in epilepsy patients taking topiramate.

children on topiramate are at a risk of renal tubular acidosis and subsequent development of renal stones. sodium bicarbonate has been shown to reduce renal tubular acidosis in other populations. to date, no data exist on the efficacy of correction of renal tubular acidosis in pediatric patients on topiramate. we are proposing to investigate the efficacy of 4 weeks of oral sodium bicarbonate therapy to reduce tubular acidosis in patients on topiramate.

Eligibility criteria:
inclusion criteria: * patients with epilepsy receiving oral topiramate for a minimum of 3 months exclusion criteria: * pre-existing renal impairments (ie nephropathy, primary nephritis) * receiving other medications or diet therapies that may influence renal function or urine acidity/ citrate concentration

Keywords: topiramate epilepsy sodium bicarbonate urine alkalinization
building long-term academic success through ongoing fun fitness program

Conditions: Reading Disorder

Summary: the purpose of the research study is to investigate if daily motor activities, including fitness activities, gross motor skills, fine motor skills, and motor coordination activities result in physiological, cognitive, and behavioral benefits to children at odyssey academy. the study will compare students' performance after intervention by comparing an intervention period to a standard care period, and comparing intervention students to students engaged in standard school activities in the area of academic performance.

the objective of this study is to track if daily participation in motor lab activities for school age children improves their academic performance. academic performance is associated with motor skills, coordination, and executive function. our objectives are to determine if daily participation in motor lab activities changes these skills, to better understand these relationships, track outcomes of children participating in motor lab intervention compared to non-intervention and children receiving standard level of care in the school, and to be able to follow the intervention students over time. the specific aims of the study are: 1. to investigate whether gross motor skills, fine motor skills, and physical fitness, predict executive function skills. 2. to determine the relationship between these variables and academic performance. 3. to examine the relationship between participation in motor lab activities and measures of change in fitness, gross motor skills, fine motor skills, executive function, and academic performance. 4. to evaluate if participation in daily motor lab activities predicts fitness level, gross motor skills, fine motor skills, executive function, and academic success at the end of the school year and in the next school year.

Eligibility criteria:
inclusion criteria: * students in grades kindergarten through fourth grade, * students below grade level in reading * in odyssey academy's reading program exclusion criteria: * students that are not part of the specialized reading program at odyssey academy * are unwilling to participate in the motor lab intervention * lack conversational ability in the use of the english language.
optimizing health among children with congenital heart defects

Conditions: Congenital Heart Defects

Summary: quality of life and heart health are intimately connected to childhood physical activity participation (pap). physical activity is critical to childhood growth, development, learning, socialization, and quality of life and is an essential component of life-long heart health. research by the investigators of this study and others has shown that low pap levels are common among children with heart defects, and that these sedentary lifestyles are not related to exercise capacity, medical status or heart function.

therefore, we hypothesize that psychosocial factors are important determinants of pap in this population. our most recent research with children who have univentricular heart indicates that gross motor skill and psychosocial factors are significant correlates of pap. important psychosocial factors include self-efficacy for activity, uncertainty about activity, and inaccurate perceptions of the child's pap level, options, and abilities. this study seeks to determine whether gross motor skill and psychosocial factors influence pap among children with a broad spectrum of cardiac defects. it will also determine the optimal changes to clinical care needed to encourage children with heart defects to develop health-related active lifestyles. we propose a prospective, randomized, cross-over preliminary clinical trial utilizing both quantitative and qualitative assessments. through the cross-over design, each subject will complete both interventions (information, demonstration), with the order of intervention delivery randomly determined. quantitative assessments will document moderate-to-vigorous physical activity (mvpa), gross motor skill, and health-related fitness. qualitative assessments will evaluate parent/child anxiety about pap and psychosocial factors influencing pap. all factors will be assessed at each data collection point.

Eligibility criteria:
inclusion criteria: * successful repair of one of the following congenital heart defects: transcatheter device closure of atrial septal defect (asd), arterial switch repair of transposition of the great arteries (tga), surgical repair of tetralogy of fallot (tof), or fontan procedure for a functionally univentricular heart (uvh). * at least one year after most recent open heart surgery. * 4 to 11 years of age and attending elementary school at first study visit. exclusion criteria: * identification of exercise contraindications/limitations by the responsible cardiologist. * other disabilities or medical conditions that may influence pap. children who achieve 90 minutes of mvpa on 5 or more days per week during the baseline assessment will be excluded from the intervention phase. the study interventions are not designed to increase mvpa among children who already achieve the health canada guidelines for pap.

Keywords: congenital physical activity participation moderate-to-vigorous physical activity